Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting.
Shanshan HuYilai WuJiajie LuanShuowen WangGuorong FanPublished in: Journal of cancer research and clinical oncology (2023)
T-DXd appears to be not cost effective compared with T-DM1 for HER2-positive mBC patients previously treated with trastuzumab and a taxane.